in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..
..
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention...
04:49
.
.
. tusk made his remarks about the u.s. president's reliability before he chaired a meeting in bulgaria of the 28 leaders whose countries make up the world's biggest trading bloc..